For instance, the number of nonvertebral fractures prevented per 100 women receiving bisphosphonates increased from 1.0 at 12 months to 1.5 at 18 months.

For higher glucocorticoid doses, there was a negative association with BMD in unadjusted analyses, but this was attenuated after accounting for age, sex, menopause status, BMI, disease duration, alkaline phosphatase levels, and the use of denosumab and bisphosphonates.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

The risk for hip fracture is higher during a treatment break from risedronate than it is during a break from alendronate, study findings indicate.

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

How will the FAST trial results impact regulatory guidance & clinical practice?

However, just 46.6% of participants reported being prescribed calcium and vitamin D at baseline, while only 4.5% of those aged less than 65 years and 21.6% of those aged 65 years or older were prescribed medications such as bisphosphonates, hormone replacement therapy, or strontium.

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

In light of this, Ensrud and Schousboe say that “some organizations recommend temporary transition to an oral bisphosphonate in patients receiving denosumab treatment for whom continued treatment is not feasible within 7 to 8 months of their most recent injection,” given the longer half-life of bisphosphonates in bone. m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 30 July 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe.

Denosumab significantly increases bone mineral density in people with glucocorticoid-induced osteoporosis and may be more effective than bisphosphonates, show the results of a systematic review and meta-analysis.

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

Explain the risks of long-term bisphosphonate therapy Identify which patients are suitable for a drug holiday Compare bisphosphonates with denosumab, and explain why denosumab should not be followed by a drug holiday

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

“Estimating the balance between the potential antifracture benefits and harms of long-term use of bisphosphonates is challenging,” note Fink and co-authors.